RxDoctor Payments Data

Kenneth Fugate, MD

Internal Medicine · Punxsutawney, PANPI 1376530386

Payments from drug & device makers

$6,834in general payments, 2019–2025

Across 352 payments — averaging $19.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$2K
  • Johnson & Johnson$926
  • Pfizer$864
  • Lilly USA, LLC$521
  • Novartis$487
  • Astellas Pharma US Inc$419
  • plus $2K from 17 others

What the payments were for

  • Food & beverage$6,71898%
  • Education$1152%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,834 in reported general payments places this provider in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

See all internal medicine providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$33,162
Medicare patients
88
Services billed
390

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban116$93,551
XareltoRivaroxaban46$50,656
OzempicSemaglutide55$46,687
JardianceEmpagliflozin49$36,491
TrulicityDulaglutide36$32,854
TradjentaLinagliptin24$29,426
JanuviaSitagliptin Phosphate25$20,127
MyrbetriqMirabegron28$15,049
LinzessLinaclotide25$13,202
EntrestoSacubitril/Valsartan11$7,069
Fluticasone-SalmeterolFluticasone Propion/Salmeterol28$5,604
Atorvastatin Calcium308$4,487
Valsartan107$4,271
Potassium Chloride166$3,512
Rosuvastatin Calcium117$3,128

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$864$93,551116 claims
Boehringer IngelheimJardiance, Tradjenta$304$65,91773 claims
Johnson & JohnsonXarelto$926$50,65646 claims
Novo NordiskOzempic$1,706$46,68755 claims
Lilly USA, LLCTrulicity$521$32,85436 claims
MerckJanuvia$15$20,12725 claims
AbbVieLinzess, Synthroid$152$16,29699 claims
Astellas Pharma US IncMyrbetriq$419$15,04928 claims
NovartisEntresto$487$7,06911 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 5,705 internal medicine providers in Pennsylvania.

Other internal medicine in Punxsutawney

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →